Enteric coated oral pharmaceutical to erode kidney stones
US7563460B2 · kind B2 · utility
0Cited by
11References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 25, 2005 |
| Grant date | Jul 21, 2009 |
| Priority date | — |
| Expiry date | May 10, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/195
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A treatment protocol by which a renal stone patient is administered a chelating agent, generally once a day and preferably by mouth, during a treatment phase and is later administered the same chelating agent once a week, during a “maintenance” phase. The chelating agent is most preferably ethylene diamine tetraacetic acid (EDTA) and may be provided in a dosage form having an enteric coating and at least one external cathode and at least one external anode to create a galvanic current upon contact of the dosage form with the patient's intestinal contents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.